Trial Profile
A Phase I/II Safety, Pharmacokinetic, and Pharmacodynamic Study of APS001F With Flucytosine and Maltose for the Treatment of Advanced and/or Metastatic Solid Tumors
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 13 May 2021
Price :
$35
*
At a glance
- Drugs APS 001F (Primary) ; Flucytosine; Maltose
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Anaeropharma Science
- 10 May 2021 Planned End Date changed from 1 Feb 2021 to 1 May 2021.
- 10 May 2021 Planned primary completion date changed from 1 Feb 2021 to 1 May 2021.
- 10 May 2021 Status changed from recruiting to suspended.